Ticagrelor in Patients with Stable Coronary Disease and Diabetes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear. METHODS: In this randomized, double-blind trial, we assigned patients who were 50 years of age or older and who had stable coronary artery disease and type 2 diabetes mellitus to receive either ticagrelor plus aspirin or placebo plus aspirin. Patients with previous myocardial infarction or stroke were excluded. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria. RESULTS: A total of 19,220 patients underwent randomization. The median follow-up was 39.9 months. Permanent treatment discontinuation was more frequent with ticagrelor than placebo (34.5% vs. 25.4%). The incidence of ischemic cardiovascular events (the primary efficacy outcome) was lower in the ticagrelor group than in the placebo group (7.7% vs. 8.5%; hazard ratio, 0.90; 95% confidence interval [CI], 0.81 to 0.99; P = 0.04), whereas the incidence of TIMI major bleeding was higher (2.2% vs. 1.0%; hazard ratio, 2.32; 95% CI, 1.82 to 2.94; P<0.001), as was the incidence of intracranial hemorrhage (0.7% vs. 0.5%; hazard ratio, 1.71; 95% CI, 1.18 to 2.48; P = 0.005). There was no significant difference in the incidence of fatal bleeding (0.2% vs. 0.1%; hazard ratio, 1.90; 95% CI, 0.87 to 4.15; P = 0.11). The incidence of an exploratory composite outcome of irreversible harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was similar in the ticagrelor group and the placebo group (10.1% vs. 10.8%; hazard ratio, 0.93; 95% CI, 0.86 to 1.02). CONCLUSIONS: In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. (Funded by AstraZeneca; THEMIS ClinicalTrials.gov number, NCT01991795.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (201,202).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“However, a higher incidence of major bleeding, including intracranial hemorrhage, was noted with dual antiplatelet therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [201]
In the citing paper
“Similarly, the addition of ticagrelor to aspirin reduced the risk of ischemic cardiovascular events compared with aspirin alone in people with diabetes and stable coronary artery disease (189,190).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [189]
In the citing paper
“Thus, an unfavourable benefit-risk profile is associated with adding ticagrelor to ASA in this setting.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
In the citing paper
“Over a median 3.3 years of follow-up, the primary efficacy outcome of CV death, MI, or stroke showed a marginal 10% RR reduction by ticagrelor vs. placebo, while both Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleeding were significantly increased.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [302]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Self-citationLong-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citationTwelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Self-citationBhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.03.025 · Cited by 805
Self-citationVranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Self-citation
Cited by
Items 201–300 of 365
König, C. S., Mann, A., McFarlane, R., Marriott, J. F., Price, M. J., & Ramachandran, S. (2023) · Biomedicines · doi:10.3390/biomedicines11123208 · Cited by 5
Antithrombotic Therapy in Patients with Chronic Coronary Syndromes
Mazzone, P. M., Spagnolo, M., & Capodanno, D. (2024) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2024.06.004 · Cited by 7
Diretriz de Síndrome Coronariana Crônica – 2025
César, L. A. M., Gowdak, L. H. W., Pavanello, R., Ferreira, J. F. M., Mioto, B. M., Poppi, N. T., Mendonça, C. J. L., Beck, A. L. D. S., de Brito, A. S. X., Abizaid, A., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250619 · Cited by 31
Verma, S., Eikelboom, J. W., Al-Omran, M. A., Choi, R., Heffernan, M., Teoh, H., & Bhatt, D. L. (2020) · Med · doi:10.1016/j.medj.2020.05.003 · Cited by 4
Self-citationTargeting multiple domains of residual cardiovascular disease risk in patients with diabetes
Patel, K. V., & Vaduganathan, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000762 · Cited by 4
EVOO’s Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?
Amodeo, S., Mirarchi, L., Seidita, A., Citarrella, R., Licata, A., Soresi, M., Iovanna, J., & Giannitrapani, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710120 · Cited by 5
Koziolova, N. A., Polyanskaya, Е. А., & Миронова, С. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-4-7-24 · Cited by 6
Parker, W. A., Angiolillo, D. J., Rollini, F., Franchi, F., Bonaca, M. P., Bhatt, D. L., Steg, P. G., Orme, R. C., Thomas, M. R., Judge, H. M., et al. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107145 · Cited by 4
Self-citationZou, Y., Yang, S., Wang, S., Lv, B., Xiu, L., Li, L., Lee, S. W. L., Chin, C. T., Pocock, S., Huo, Y., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23322 · Cited by 5
Nicolas, J., Razuk, V., Giustino, G., & Mehran, R. (2021) · Future Cardiology · doi:10.2217/fca-2021-0014 · Cited by 5
Optimizing selection of P2Y 12 inhibiting therapy: clopidogrel, prasugrel or ticagrelor
Galli, M., Simeone, B., Gragnano, F., D’Amario, D., Sarto, G., Frati, G., Greco, E., Calabrò, P., Sciarretta, S., Mehran, R., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2576607 · Cited by 4
Dual antiplatelet therapy escalation and de-escalation
Greco, A., Leo, G. D., Finocchiaro, S., Imbesi, A., & Capodanno, D. (2026) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf173 · Cited by 10
Patti, G., Fattirolli, F., Luca, L. D., Renda, G., Marcucci, R., Parodi, G., Perna, G. P., Andreotti, F., Ghiglieno, C., Fedele, F., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111783 · Cited by 3
Jiang, Z., Liu, L., & Bundhun, P. K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01354-5 · Cited by 3
Würtz, M., Olesen, K. K. W., Bhatt, D. L., Yusuf, S., Muehlhofer, E., Eikelboom, J. W., & Mæng, M. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae017 · Cited by 4
Self-citationShould We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?
Chandiramani, R., Mehta, A., Blumenthal, R. S., & Williams, M. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01234-2 · Cited by 3
Planchat, A., Gencer, B., Degrauwe, S., Musayeb, Y., Roffi, M., & Iglesias, J. F. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1436332 · Cited by 5
Canonico, M. E., Avvedimento, M., Piccolo, R., Hess, C. N., Bardi, L., Ilardi, F., Giugliano, G., Franzone, A., Gargiulo, G., Berkowitz, S. D., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.03.010 · Cited by 4
Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial
Abtan, J., Bhatt, D. L., Held, C., Simon, T., Fox, K. M., Mehta, S. R., Harrington, R. A., Gao, Q., Leiter, L. A., & Steg, P. G. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.011035 · Cited by 3
Self-citationBaber, U., Spirito, A., Sartori, S., Angiolillo, D. J., Briguori, C., Cohen, D. J., Collier, T. J., Dangas, G., Dudek, D., Escaned, J., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.09.008 · Cited by 3
Self-citationLow expression of Notch1 may be associated with acute myocardial infarction
Zhang, Q., Meng, H., Wang, X., Chen, Y., Yan, Z., Ruan, J., & Meng, F. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1367675 · Cited by 3
Sykes, R., Briscoe, M., Krysztofiak, T., Peck, O. H., Mangion, K., & Berry, C. (2021) · Open Heart · doi:10.1136/openhrt-2021-001633 · Cited by 3
P2Y12-inhibitor monotherapy after coronary stenting: are all P2Y12-inhibitors equal?
van der Sangen, N. M. R., Küçük, I. T., ten Berg, J. M., Beijk, M. A. M., Delewi, R., den Hartog, A. W., Appelman, Y., Verouden, N., Kikkert, W. J., Henriques, J. P. S., et al. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2104248 · Cited by 3
Wittbrodt, E. T., Bhalla, N. P., Sundell, K. A., Hunt, P. R., Wong, N. D., Kuster, M., & Mellström, C. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107859 · Cited by 3
Linder, M., & Andersen, M. T. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5387 · Cited by 5
What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease?
Otieno, B., Ibecheozor, C., & Williams, M. S. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01108-z · Cited by 3
Extending the Product Label for Ticagrelor: Looking Under the FDA Hood
Armstrong, P. W. (2021) · Circulation · doi:10.1161/circulationaha.121.055907 · Cited by 3
Wheeler, M., Chan, N., & Eikelboom, J. W. (2020) · Future Cardiology · doi:10.2217/fca-2020-0068 · Cited by 2
Ahlers, M. J., John, S., Bhatia, H. S., Le, V. T., & Taub, P. R. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101265 · Cited by 5
Laudani, C., Ortega‐Paz, L., Capodanno, D., & Angiolillo, D. J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586110 · Cited by 2
Clinical pharmacology of antiplatelet drugs: implications for personalized therapy
Wichaiyo, S. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-03998-9 · Cited by 2
Zhong, M., Wu, X., Liu, Y., Mao, Y., Liu, M., Liu, X., & Liu, Q. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07882-7 · Cited by 5
Self-citationOrok, E. N., Adeniyi, F. R., & Akawa, O. B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105139 · Cited by 4
Liu, C., & Ma, L. (2023) · Medicine · doi:10.1097/md.0000000000036429 · Cited by 2
Ji, Y., Wang, B., Wu, G., Zhang, Y., Wang, Q., & Zhou, M. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231213262 · Cited by 3
Ticagrelor — a legend of modern cardiology
Gilyarevskiy, S. R. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6052 · Cited by 2
Fakhri, Y. A., & Al-Ani, A. W. (2025) · Iraqi Journal of Science · doi:10.24996/ijs.2025.66.5.4 · Cited by 3
Wilczek, K. L., Chodór, P., Dyrbuś, M., Hawranek, M., Włoch, Ł., Pyka, Ł., Hrapkowicz, T., Zembala, M. O., Kalarus, Z. F., & Gąsior, M. (2020) · Advances in Interventional Cardiology · doi:10.5114/aic.2020.101769 · Cited by 2
Antiplatelet and antithrombotic therapy in diabetic patients recent updates
Ashfaq, M., Hussain, M. A., Syed, J., Mohammed, A. M., & Nayak, S. P. S. (2021) · International journal of applied research · doi:10.5281/zenodo.5469492 · Cited by 4
Kong, Q., Ma, X., Zhao, X., Chen, F., & Hou, C. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02085-9 · Cited by 2
Yap, J. J. L., Chew, D. P., Stone, G. W., & Tan, J. W. C. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.48 · Cited by 2
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Morrison, J. T., Hsia, J. A., & Bonaca, M. P. (2021) · Heart International · doi:10.17925/hi.2021.15.1.14 · Cited by 2
Ng, A. K., Ng, P. Y., Ip, A., Lam, L. T., & Siu, C. (2022) · Open Heart · doi:10.1136/openhrt-2021-001861 · Cited by 2
Ducrocq, G., Bhatt, D. L., Lee, J., Kui, N., Fox, K. M., Harrington, R. A., Leiter, L. A., Mehta, S. R., Kiss, R. G., James, S. K., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.03.008 · Cited by 2
Self-citationAbtan, J., Bhatt, D. L., Elbez, Y., Ducrocq, G., Goto, S., Smith, S. C., Ohman, E. M., Eagle, K. A., Fox, K. M., Harrington, R. A., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.132 · Cited by 2
Self-citationDual pathway inhibition in atherothrombosis prevention: yes, now we can!
SUMMARIA, F., Biondi‐Zoccai, G., Romagnoli, E., Mamas, M. A., FRANCHI, F., Severino, P., LAVALLE, C., VERSACI, F., Gaspardone, A., & Bhatt, D. L. (2021) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05867-1 · Cited by 2
Self-citationTicagrelor with or without Aspirin after PCI
Baber, U., Dangas, G., & Mehran, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmc1917041 · Cited by 2
Full transparency of ticagrelor trials in coronary artery disease should be warranted
Ennezat, P., Guerbaaï, R.-A., LeJemtel, T. H., & Hansen, M. (2022) · Hospital Practice · doi:10.1080/21548331.2022.2049099 · Cited by 2
Pavasini, R., & Campo, G. C. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317693 · Cited by 2
Ahmed, R., de Souza, R. J., Li, V., & Anand, S. S. (2022) · medRxiv · doi:10.1101/2022.06.28.22275821 · Cited by 4
Optimal Antiplatelet Therapy Revisited
Bhatt, D. L. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.040 · Cited by 3
Self-citationThe role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era
Vogt, J. C., Manning, P. G., Sheikh, O., Aronow, H. D., CHILTON, R. J., & Cigarroa, J. E. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29089 · Cited by 1
Management of Acute Coronary Syndromes Beyond the First Year: A Canadian Clinical Practice Survey
Bui, K. A., Matteau, A., Elbarouni, B., Bainey, K. R., Fordyce, C. B., Bagai, A., Rose, B. F., Lutchmedial, S. R., Leis, B. T., Lavoie, A., et al. (2020) · CJC Open · doi:10.1016/j.cjco.2020.08.002 · Cited by 1
Baptista, S. B., de Morais, G. P., Morais, L. A., Costa, J., Vinhas, H., Campos, G., Ferreira, P. C., Vale, N. C., Seixo, F., Santos, M. B., et al. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.03.006 · Cited by 2
Antiplatelet Therapy in Coronary Artery Disease
Laudani, C., Capodanno, D., & Angiolillo, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_9 · Cited by 1
Wang, Y., Fuerte-Hortigon, A., Chetty, S., Garah, M., Sarmiento, R. J., Barber, P. A., Saposnik, G., Lee, D. S., Singnurkar, A., Swartz, R. H., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.358 · Cited by 6
Antiplatelet Therapy in Stable Coronary Artery Disease
Alzahrani, R. S., Talmesany, T., Alghamdi, A. A., Alhamyani, A. F., Alghamdi, D. A., Alghamdi, L. S., Alzahrani, M. A., Aljohani, S. D., Alsaif, A. K., & Azzam, A. Y. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102633 · Cited by 1
Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines
Bershtein, L. L., Владимировна, З. Е., & Gumerova, V. E. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-10-02 · Cited by 1
Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor
Costa, T. G. R., Katz, M., Lemos, P. A., Guerra, J. C. D. C., Franken, M., & Pesaro, A. E. P. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022ao7001 · Cited by 2
Bendary, A., Zarif, B., Badran, H. M., Shokry, K., & Kabil, H. (2023) · The Egyptian Heart Journal · doi:10.1186/s43044-023-00364-3 · Cited by 1
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year
Akhtar, K. H., & Baber, U. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.12.003 · Cited by 2
Farida, U., Wahyuni, K. S. P. D., & Paringsih, D. P. M. (2023) · Journal Syifa Sciences and Clinical Research · doi:10.37311/jsscr.v5i2.20833 · Cited by 4
Cardiometabolic diseases—Recent advance in antithrombotic and thrombolytic therapies
Nikolovski, S. S., Jeske, W. P., & Fareed, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00006-1 · Cited by 1
Bian, L., Qiu, M., Li, J., Zhang, L., Hunt, P. R., Kuster, M., & Han, Y. (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000133 · Cited by 2
Li, L., Sun, H., Jin, Z., Li, J., Fang, Y., Zuo, L., Sun, P., Li, Y., Richards, M., Foo, R., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.021 · Cited by 1
Koziolova, N. A., Karavaev, P. G., & Veklich, A. S. (2020) · Kardiologiia · doi:10.18087/cardio.2020.4.n1042 · Cited by 1
Shyamkumar, K., Hirsh, J., Bhagirath, V. C., Sinha, S., Xu, K., Ginsberg, J. S., Díaz, R., Eikelboom, J. W., & Chan, N. (2020) · Future Cardiology · doi:10.2217/fca-2020-0013 · Cited by 1
Ticagrelor in the Management of Coronary Artery Disease
Loganath, K., Adamson, P. D., & Moss, A. J. (2020) · Future Cardiology · doi:10.2217/fca-2020-0108 · Cited by 1
Prevenzione secondaria nella malattia coronarica
Sorbets, E., Lallmahomed, E., Kretz, S., Cinaud, A., Vallée, A., Lelong, H., Blachier, V., & Blacher, J. (2021) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(21)44575-4 · Cited by 1
Kim, M., Park, K. W., Lee, H. S., Ki, Y., Kang, J., Kim, C., Han, J., Yang, H., Kang, H., Koo, B., et al. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29682 · Cited by 3
Considerations for use of direct oral anticoagulants in arterial disease
Siegal, D. M., & Anand, S. S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12502 · Cited by 2
Liuzzo, G., & Patrono, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab673 · Cited by 1
Adik-Pathak, L., Shirodkar, S., & Gupta, A. (2022) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0073 · Cited by 1
Differential effect of ticagrelor on irreversible harms in diabetes – Authors' reply
Bhatt, D. L., & Steg, P. G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30479-7 · Cited by 1
Self-citationBenefits of Ticagrelor Plus Aspirin According to Diabetes-Related Factors
Dillinger, J., & Henry, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.319 · Cited by 1
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
Self-citationTicagrelor reduces ischaemic risk in patients with CAD and diabetes
Huynh, K. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0281-3
Ticagrelor bei KHK-Patienten mit Diabetes
Overbeck, P. (2019) · CardioVasc · doi:10.1007/s15027-019-1581-6
Aradi, D., Komócsi, A., Kancz, S., Nagy, G. G., Kiss, R. G., & Merkely, B. P. (2019) · Cardiologia Hungarica · doi:10.26430/chungarica.2019.49.4.267
DAPT may be beneficial in patients with diabetes and stable CAD
Tanzi, M. G. (2019) · Pharmacy Today · doi:10.1016/j.ptdy.2019.11.028
Cardiology update – Third quarter
Yadav, S. (2019) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_60_19
Riwaroksaban — następny krok w leczeniu choroby niedokrwiennej serca
Grajek, S., & Olasińska‐Wiśniewska, A. (2019) · Choroby Serca i Naczyń · doi:10.5603/chsin.2019.0032
Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen: Update 2019
Olivier, C. B., Bode, C., & Dürschmied, D. (2020) · Der Klinikarzt · doi:10.1055/a-1110-6764
(2016) · Dental Abstracts · doi:10.1016/j.denabs.2016.07.050
Канорский, С. Г. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-06-04 · Cited by 38
Consenso AURORA: risco cardiovascular na pessoa com diabetes mellitus tipo 2
de Família, M., Maricoto, T., Antunes, J. P., de Família, M., Pereira, M. R., de Família, M., Corte-Real, S., de Família, M., Taveira‐Gomes, T., de Família, M., et al. (2020) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v36i3.12744 · Cited by 3
Differential effect of ticagrelor on irreversible harms in diabetes
Chi, G., & Marszalek, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30486-4
Cygulska, K. M., & Kasprzak, J. D. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0037
How should the ticagrelor be used? The point after the TWILIGHT and THEMIS-PCI studies
Gatto, L., & Prati, F. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa139
Platelet physiology and pharmacology—relevant considerations for patient care
Lee, C. H., & Angiolillo, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820536-5.00005-7
Ranard, L. S., & Brener, S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820536-5.00002-1
Cao, D., Dangas, G., & Mehran, R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019889
The Association between Co-Administration of Omeprazole and Clopidogrel and Cardiovascular Outcomes
Azab, A. N., Shmulevich, E., Gilutz, H., Shvartsur, R., & Friger, M. D. (2021) · Austin Journal of Pharmacology and Therapeutics · doi:10.26420/austinjpharmacolther.2021.1126 · Cited by 1
Continuing use of aspirin in total knee arthroplasty: safe or not?Preprint
Li, Z., Xiang, S., Du, Y., Bian, Y., Feng, B., & Weng, X. (2021) · Research Square · doi:10.21203/rs.3.rs-492900/v1
Prevención secundaria en el paciente coronario
Sorbets, E., Lallmahomed, E., Kretz, S., Cinaud, A., Vallée, A., Lelong, H., Blachier, V., & Blacher, J. (2021) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(21)44686-6
Ticagrelor and CABG for acute coronary syndrome?—It is complicated
Sandner, S. E., & Gaudino, M. F. L. (2021) · Journal of Cardiac Surgery · doi:10.1111/jocs.15678
Tantry, U. S., & Gurbel, P. A. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16080
Metadata
- Authors
- Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., Leonsson-Zachrisson, M., Liu, Y., Opolski, G., Zateyshchikov, D., Ge, J., Nicolau, J. C., Corbalán, R., Cornel, J. H., Widimský, P., & Leiter, L. A.
- Affiliations
- From the French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Université de Paris, INSERM Unité 1148 (P.G.S.), Assistance Publique–Hôpitaux de Paris (P.G.S., T.S.), Hôpital Saint Antoine, Department of Clinical Pharmacology, Unité de Recherche Clinique (T.S.), and Sorbonne Université (T.S.) — all in Paris; the National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London (P.G.S., K.F.); Brigham and Women’s Hospital Heart and...
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Uppsala University (SE)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-03
- Volume
- 381
- Issue
- 14
- Pages
- 1309-1320
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2970797239
- Cited by
- 365
- References
- 32
- Citations by year
- 2026: 27 · 2025: 30 · 2024: 34 · 2023: 48 · 2022: 56 · 2021: 81 · 2020: 75 · 2019: 12
- FWCI
- 40.45
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, stable coronary artery disease, type 2 diabetes, antiplatelet therapy, aspirin, major bleeding, intracranial hemorrhage, cardiovascular events, irreversible harm, treatment discontinuation, P2Y12 inhibitors, elderly patients, cardiovascular risk stratification, bleeding risk assessment, risk-benefit assessment
- MeSH terms
- Ticagrelor, Aged, Aspirin, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Incidence, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.